Health-Related Quality of Life for Patients Receiving Tumor Treating Fields for Glioblastoma

BackgroundTo date, there has been no large-scale, real-world study of the health-related quality of life outcomes for patients using tumor treating fields (TTFields) therapy for glioblastoma (GBM) treatment.MethodsA survey was mailed to 2,815 patients actively using TTFields for treatment of GBM in...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Joshua D. Palmer, Gordon Chavez, Wesley Furnback, Po-Ya Chuang, Bruce Wang, Christina Proescholdt, Chao-Hsiun Tang
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	glioblastoma tumor treating fields quality of life EQ-5D real-world evidence Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/c221ce71a4484dd5b76a341b782eca83
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c221ce71a4484dd5b76a341b782eca83
record_format	dspace
spelling	oai:doaj.org-article:c221ce71a4484dd5b76a341b782eca832021-12-02T11:57:28ZHealth-Related Quality of Life for Patients Receiving Tumor Treating Fields for Glioblastoma2234-943X10.3389/fonc.2021.772261https://doaj.org/article/c221ce71a4484dd5b76a341b782eca832021-12-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.772261/fullhttps://doaj.org/toc/2234-943XBackgroundTo date, there has been no large-scale, real-world study of the health-related quality of life outcomes for patients using tumor treating fields (TTFields) therapy for glioblastoma (GBM) treatment.MethodsA survey was mailed to 2,815 patients actively using TTFields for treatment of GBM in the USA (n = 2,182) and Europe (n = 633). The survey included patient-reported demographic and clinical information, as well as EuroQol’s EQ-5D-5L and visual analogue scale (EQ-VAS) overall health score.ResultsA total of 1,106 applicable patients responded to the survey (USA = 782 and Europe = 324), with a mean age of 58.6 years (SD = 12.3). The average time since diagnosis and time using TTFields were 21.5 months (SD = 25.1) and 13.5 months (SD = 13.2), respectively. Over 61% of patients had been diagnosed at least 1 year prior and 28.4% at least 2 years prior; 45 patients (4.2%) had been diagnosed at least 5 years prior. Progressed disease was reported in 307 patients, while 690 reported non-progressed disease. Regression analyses showed that GBM disease progression and older age had predictable negative associations (p < 0.001) with most EQ-5D-5L dimensions and the EQ-VAS. However, longer time since diagnosis was associated with improved self-care (p < 0.05), usual activities (p < 0.01), and EQ-VAS (p < 0.05) overall and in patients with progressed disease (p < 0.01, p < 0.05, and p < 0.01, respectively). Additionally, longer time using TTFields was associated with improved mobility (p < 0.05), self-care (p < 0.001), usual activities (p < 0.01), and EQ-VAS (p < 0.01) overall; with improved EQ-VAS in progression-free patients (p < 0.05); and with improved mobility (p < 0.05), self-care (p < 0.01), usual activities (p < 0.05), and EQ-VAS (p < 0.05) in patients with progressed disease.ConclusionThis is the largest real-world study of patient-reported quality of life in GBM and TTFields treatment to date. It shows unsurprising negative associations between quality of life and disease progression and older age, as well as more novel, positive associations between quality of life and longer time since diagnosis and time using TTFields therapy.Joshua D. PalmerGordon ChavezWesley FurnbackPo-Ya ChuangBruce WangChristina ProescholdtChao-Hsiun TangFrontiers Media S.A.articleglioblastomatumor treating fieldsquality of lifeEQ-5Dreal-world evidenceNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	glioblastoma tumor treating fields quality of life EQ-5D real-world evidence Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	glioblastoma tumor treating fields quality of life EQ-5D real-world evidence Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Joshua D. Palmer Gordon Chavez Wesley Furnback Po-Ya Chuang Bruce Wang Christina Proescholdt Chao-Hsiun Tang Health-Related Quality of Life for Patients Receiving Tumor Treating Fields for Glioblastoma
description	BackgroundTo date, there has been no large-scale, real-world study of the health-related quality of life outcomes for patients using tumor treating fields (TTFields) therapy for glioblastoma (GBM) treatment.MethodsA survey was mailed to 2,815 patients actively using TTFields for treatment of GBM in the USA (n = 2,182) and Europe (n = 633). The survey included patient-reported demographic and clinical information, as well as EuroQol’s EQ-5D-5L and visual analogue scale (EQ-VAS) overall health score.ResultsA total of 1,106 applicable patients responded to the survey (USA = 782 and Europe = 324), with a mean age of 58.6 years (SD = 12.3). The average time since diagnosis and time using TTFields were 21.5 months (SD = 25.1) and 13.5 months (SD = 13.2), respectively. Over 61% of patients had been diagnosed at least 1 year prior and 28.4% at least 2 years prior; 45 patients (4.2%) had been diagnosed at least 5 years prior. Progressed disease was reported in 307 patients, while 690 reported non-progressed disease. Regression analyses showed that GBM disease progression and older age had predictable negative associations (p < 0.001) with most EQ-5D-5L dimensions and the EQ-VAS. However, longer time since diagnosis was associated with improved self-care (p < 0.05), usual activities (p < 0.01), and EQ-VAS (p < 0.05) overall and in patients with progressed disease (p < 0.01, p < 0.05, and p < 0.01, respectively). Additionally, longer time using TTFields was associated with improved mobility (p < 0.05), self-care (p < 0.001), usual activities (p < 0.01), and EQ-VAS (p < 0.01) overall; with improved EQ-VAS in progression-free patients (p < 0.05); and with improved mobility (p < 0.05), self-care (p < 0.01), usual activities (p < 0.05), and EQ-VAS (p < 0.05) in patients with progressed disease.ConclusionThis is the largest real-world study of patient-reported quality of life in GBM and TTFields treatment to date. It shows unsurprising negative associations between quality of life and disease progression and older age, as well as more novel, positive associations between quality of life and longer time since diagnosis and time using TTFields therapy.
format	article
author	Joshua D. Palmer Gordon Chavez Wesley Furnback Po-Ya Chuang Bruce Wang Christina Proescholdt Chao-Hsiun Tang
author_facet	Joshua D. Palmer Gordon Chavez Wesley Furnback Po-Ya Chuang Bruce Wang Christina Proescholdt Chao-Hsiun Tang
author_sort	Joshua D. Palmer
title	Health-Related Quality of Life for Patients Receiving Tumor Treating Fields for Glioblastoma
title_short	Health-Related Quality of Life for Patients Receiving Tumor Treating Fields for Glioblastoma
title_full	Health-Related Quality of Life for Patients Receiving Tumor Treating Fields for Glioblastoma
title_fullStr	Health-Related Quality of Life for Patients Receiving Tumor Treating Fields for Glioblastoma
title_full_unstemmed	Health-Related Quality of Life for Patients Receiving Tumor Treating Fields for Glioblastoma
title_sort	health-related quality of life for patients receiving tumor treating fields for glioblastoma
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/c221ce71a4484dd5b76a341b782eca83
work_keys_str_mv	AT joshuadpalmer healthrelatedqualityoflifeforpatientsreceivingtumortreatingfieldsforglioblastoma AT gordonchavez healthrelatedqualityoflifeforpatientsreceivingtumortreatingfieldsforglioblastoma AT wesleyfurnback healthrelatedqualityoflifeforpatientsreceivingtumortreatingfieldsforglioblastoma AT poyachuang healthrelatedqualityoflifeforpatientsreceivingtumortreatingfieldsforglioblastoma AT brucewang healthrelatedqualityoflifeforpatientsreceivingtumortreatingfieldsforglioblastoma AT christinaproescholdt healthrelatedqualityoflifeforpatientsreceivingtumortreatingfieldsforglioblastoma AT chaohsiuntang healthrelatedqualityoflifeforpatientsreceivingtumortreatingfieldsforglioblastoma
_version_	1718394832918937600

Health-Related Quality of Life for Patients Receiving Tumor Treating Fields for Glioblastoma

Ejemplares similares